CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

by | Mar 2, 2026 | Clinical Trials | 0 comments

​ Conditions: Large-cell Lymphoma

Interventions: Biological: Rapcabtagene autoleucel (YTB323)

Sponsors: Stanford University; Novartis

Not yet recruiting Conditions: Large-cell Lymphoma
Interventions: Biological: Rapcabtagene autoleucel (YTB323)
Sponsors: Stanford University; Novartis
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *